One in four people may develop symptomatic hip osteoarthritis in his or her lifetime

Abstract

Summary Objective To estimate the lifetime risk of symptomatic hip osteoarthritis (OA). Design We analyzed data from the Johnston County Osteoarthritis Project (a longitudinal population-based study of OA in North Carolina, United States [n=3,068]). The weighted baseline sample comprised 18% blacks and 54% women, and the mean age was 63 years (range=45-93). Symptomatic hip OA was defined as a Kellgren-Lawrence (K-L) radiographic score of ≥2 (anterior-posterior pelvis x-rays) and pain, aching or stiffness on most days, or groin pain, in the same hip. Lifetime risk, defined as the proportion who developed symptomatic hip OA in at least one hip by age 85, among people who live to age 85, was modeled using logistic regression with repeated measures (through generalized estimating equations). Results Lifetime risk of symptomatic hip OA was 25.3% (95% confidence interval [CI] = 21.3–29.3). Lifetime risk was similar by sex, race, highest educational attainment, and hip injury history. We studied lifetime risk by body mass index (BMI) in three forms: at age 18; at baseline and follow-up; and at age 18, baseline and follow-up and found no differences in estimates. Conclusion The burden of symptomatic hip OA is substantial with one in four people developing this condition by age 85. The similar race-specific estimates suggest that racial disparities in total hip replacements are not attributable to differences in disease occurrence. Despite increasing evidence that obesity predicts an increased risk of both hip OA and joint replacement, we found no association between BMI and lifetime risk.

Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis

“…1 The lifetime prevalence of symptomatic hip osteoarthritis is estimated at 25.3%, 2 while that of knee osteoarthritis is even higher at 44.7%. 3 The economic burden of osteoarthritis is substantial and consists of both direct costs (such as drugs,…”

Adipose derived stem cells for regenerative therapy in osteoarticular diseases

“…Over 40 million Europeans are presently affected by OA [30]. Two studies have identified a 45% and 25% lifetime risk of developing knee and hip OA, respectively [31,32]. Furthermore, treatment is costly, currently estimated as representing 1:2.5% of gross national product [33].…”

Hip osteoarthritis surgical profiles and morbid obesity: a case series and literature review

“…The disease known as hip osteoarthritis is a common highly painful disabling joint disease with no known cure affecting a large proportion of the adult population [1,2]. One potentially preventable factor that may mediate or moderate the onset and progression of hip osteoarthritis is obesity [3].…”